Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $72.06, for a total value of $1,080,900.00. Following the transaction, the senior vice president now owns 2,669 shares in the company, valued at approximately $192,328.14. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

RGNX stock opened at $66.37 on Friday. Regenxbio Inc has a fifty-two week low of $23.25 and a fifty-two week high of $85.10. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -27.09, a PEG ratio of 14.80 and a beta of -0.49.

Regenxbio (NASDAQ:RGNX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a return on equity of 27.33% and a net margin of 44.30%. The firm had revenue of $5.31 million for the quarter. As a group, sell-side analysts expect that Regenxbio Inc will post 1.64 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Regenxbio by 12.1% in the 3rd quarter. BlackRock Inc. now owns 4,727,045 shares of the biotechnology company’s stock worth $356,893,000 after purchasing an additional 508,632 shares in the last quarter. RTW Investments LP boosted its position in shares of Regenxbio by 10.7% in the 2nd quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after purchasing an additional 201,788 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Regenxbio by 12.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 359,415 shares of the biotechnology company’s stock worth $27,136,000 after purchasing an additional 40,085 shares in the last quarter. Northern Trust Corp boosted its position in shares of Regenxbio by 21.2% in the 2nd quarter. Northern Trust Corp now owns 359,040 shares of the biotechnology company’s stock worth $25,762,000 after purchasing an additional 62,849 shares in the last quarter. Finally, Botty Investors LLC boosted its position in shares of Regenxbio by 9.0% in the 3rd quarter. Botty Investors LLC now owns 224,187 shares of the biotechnology company’s stock worth $16,926,000 after purchasing an additional 18,473 shares in the last quarter. 81.17% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have weighed in on the company. ValuEngine downgraded Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Raymond James reiterated a “buy” rating on shares of Regenxbio in a report on Monday, October 29th. Barclays upped their target price on Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. Chardan Capital upped their target price on Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 16th. Finally, BidaskClub downgraded Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $84.07.

WARNING: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/11/11/patrick-j-christmas-sells-15000-shares-of-regenxbio-inc-rgnx-stock.html.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: Technical Analysis of Stocks and What It Means

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.